Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacobus Pfisterer

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 31, 2023
Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study GroupPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2025
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observationsPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)Philipp Harter, David Gershenson, Catherine Lhomme, et al.
Gynecologic Oncology|January 6, 2016
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)Günter Emons, Christian Kurzeder, Barbara Schmalfeldt, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 31, 2018
Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry ProfilesJamie Magrill, Anthony N Karnezis, Basile Tessier-Cloutier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroupGiorgia Mangili, Domenica Lorusso, Jubilee Brown, et al.
Journal of the National Cancer Institute|September 4, 2003
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancerAndreas du Bois, Hans-Joachim Lück, Werner Meier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 16, 2015
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT StudyChristina Fotopoulou, Jalid Sehouli, Nina Ewald-Riegler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers OvariensAndreas du Bois, Beatrice Weber, Justine Rochon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II studyAlexander Burges, Pauline Wimberger, Carolin Kümper, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 31, 2023
Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study GroupPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2025
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observationsPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)Philipp Harter, David Gershenson, Catherine Lhomme, et al.
Gynecologic Oncology|January 6, 2016
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)Günter Emons, Christian Kurzeder, Barbara Schmalfeldt, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 31, 2018
Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry ProfilesJamie Magrill, Anthony N Karnezis, Basile Tessier-Cloutier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroupGiorgia Mangili, Domenica Lorusso, Jubilee Brown, et al.
Journal of the National Cancer Institute|September 4, 2003
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancerAndreas du Bois, Hans-Joachim Lück, Werner Meier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 16, 2015
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT StudyChristina Fotopoulou, Jalid Sehouli, Nina Ewald-Riegler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers OvariensAndreas du Bois, Beatrice Weber, Justine Rochon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II studyAlexander Burges, Pauline Wimberger, Carolin Kümper, et al.
Pageof 10